Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) EV/Sales
As of 25 September 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 1.8× (April 2025) to 7.8× (September 2021); the current reading is higher than 84% of that period. That is below the Diagnostics & Research industry median of 5.7× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | 3.30% |
| FY2024 | 2.8× | (18.19%) |
| FY2023 | 3.5× | 1.61% |
| FY2022 | 3.4× | (43.35%) |
| FY2021 | 6.0× | 25.12% |
| FY2020 | 4.8× | 39.31% |
| FY2019 | 3.5× | 13.96% |
| FY2018 | 3.0× | (9.30%) |
| FY2017 | 3.4× | 19.69% |
| FY2016 | 2.8× | (14.72%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 22.87% |
| Mar 2026 | 2.7× | (7.84%) |
| Dec 2025 | 2.9× | 22.27% |
| Sep 2025 | 2.4× | 0.86% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.2× |
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| CRL Charles River Laboratories International, Inc. | 4.1× |
| QGEN QIAGEN N.V. compare | 4.7× |
| MEDP Medpace Holdings, Inc. compare | 6.1× |
| RVTY Revvity Inc. compare | 6.5× |
| GH Guardant Health, Inc. compare | 20.3× |
| TWST Twist Bioscience Corporation compare | 26.2× |
| Diagnostics & Research industry median | 5.7× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement